BML Capital Management, LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
BML Capital Management, LLC disclosed 13 US equity positions worth $113.0m in its Q4 2025 13F filing. The largest position was ACRS at 38.0% of the reported book, followed by AVIR and ORMP. Against the Q3 2025 filing, it opened 3 new positions, added to 1 and reduced 3 among the top 13 holdings.
What did BML Capital Management, LLC own in Q4 2025? Top 13 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 38.0% | $42.9m | 14,250,000 | 0% | held |
| 2 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 23.7% | $26.7m | 7,490,000 | 0% | held |
| 3 | ORMP ORAMED PHARMACEUTICALS INC | 8.0% | $9.0m | 3,167,231 | 0% | held | |
| 4 | TIL INSTIL BIO INC | 6.3% | $7.1m | 645,600 | 0% | held | |
| 5 | PMVP PMV PHARMACEUTICALS INC | 5.9% | $6.6m | 5,292,000 | 0% | held | |
| 6 | KMX CARMAX INC | Consumer Cyclical | 5.3% | $6.0m | 155,000 | – | new |
| 7 | 2KZ0 KEZAR LIFE SCIENCES INC | 4.0% | $4.5m | 720,787 | 0% | held | |
| 8 | TGT TARGET CORP | Consumer Defensive | 3.2% | $3.7m | 37,500 | 275% | added |
| 9 | OM OUTSET MED INC | 1.8% | $2.0m | 543,180 | – | new | |
| 10 | PLRX PLIANT THERAPEUTICS INC | Healthcare | 1.7% | $1.9m | 1,546,137 | – | new |
| 11 | IMA IMAGENEBIO INC | 1.1% | $1.2m | 177,026 | -3% | reduced | |
| 12 | CNTB CONNECT BIOPHARMA HLDGS LTD | 1.0% | $1.2m | 408,887 | -68% | reduced | |
| 13 | LSTA LISATA THERAPEUTICS INC | 0.1% | $136.4k | 73,348 | -33% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.